Our Research

 At GHDDI, we focus on translational research – from the bench to the bedside. Our scientists conduct great science and develop new technology to accelerate drug discovery for diseases that impact global population, such as COVID-19, tuberculosis, malaria etc. With diverse pipelines constructed, GHDDI have already achieved great number of breakthroughs.




GHDDI has successfully established an industry-leading standardized matrix system that acts as a cornerstone for the development of new small molecule drugs, with a sharp focus on multiple disease areas in the realm of biology. This state-of-the-art system is powered by medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), animal laboratory, protein science and structural biology, high-throughput screening, and data science. These cutting-edge platforms play a pivotal role in drug discovery, offering unmatched precision and efficiency.




Utilizing state-of-the-art deep learning algorithms, we construct a computing module that encompasses multi-objective optimized high-throughput virtual screening, drug repositioning, and biological target identification. This module heavily relies on global data partners to establish a highly integrated database, encompassing small molecule physicochemical properties, biological activity, and clinical information. The database serves as an ideal knowledge map library and training set for the AI module. To ensure exceptional performance, we equip the module with a world-leading high-performance GPU/CPU parallel computing cluster. Additionally, we configure it with a cloud elastic high-performance scalable computing cluster, allowing for maximum daily computing volume that can handle billions of molecules.



Equipped with the cutting-edge HighRes fully automated high-throughput screening system instrumentation, HTS supports multiple types of screening methods based on biological targets and cellular phenotypes. With a screening data capacity of millions of compounds (samples)/year, the platform can save time and cost. The platform has established multiple types of compound libraries, including known activity libraries, structural diversity libraries, natural product libraries, and true pair-specific disease/target libraries, with a total of over 450,000 compounds. In addition, the platform has the ReFRAME compound library, with over 12,000 clinically safe compounds.